125 related articles for article (PubMed ID: 12856386)
1. Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects.
Mousa SA; Bozarth J; Barrett JS
J Clin Pharmacol; 2003 Jul; 43(7):727-34. PubMed ID: 12856386
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic effects of low molecular weight heparin in obese subjects following subcutaneous administration of 75 IU/kg on plasma tissue factor pathway inhibitor and nitric oxide.
Mousa SA; Johansen K
Int Angiol; 2005 Mar; 24(1):40-2. PubMed ID: 15876997
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor.
Mousa SA; Mohamed S
Thromb Haemost; 2004 Sep; 92(3):627-33. PubMed ID: 15351861
[TBL] [Abstract][Full Text] [Related]
4. The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man.
Holst J; Lindblad B; Bergqvist D; Hedner U; Nordfang O; Ostergaard P
Thromb Res; 1997 May; 86(4):343-8. PubMed ID: 9187023
[TBL] [Abstract][Full Text] [Related]
5. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins.
Alban S; Gastpar R
Thromb Haemost; 2001 May; 85(5):824-9. PubMed ID: 11372675
[TBL] [Abstract][Full Text] [Related]
6. Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins.
Bendz B; Hansen JB; Andersen TO; Ostergaard P; Sandset PM
Br J Haematol; 1999 Dec; 107(4):756-62. PubMed ID: 10606880
[TBL] [Abstract][Full Text] [Related]
7. Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment.
Brodin E; Svensson B; Paulssen RH; Nordoy A; Hansen JB
J Lab Clin Med; 2004 Nov; 144(5):246-53; discussion 226-7. PubMed ID: 15570242
[TBL] [Abstract][Full Text] [Related]
8. Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers.
Barrett JS; Hainer JW; Kornhauser DM; Gaskill JL; Hua TA; Sprogel P; Johansen K; van Lier JJ; Knebel W; Pieniaszek HJ
Thromb Res; 2001 Feb; 101(4):243-54. PubMed ID: 11248285
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primates.
Jeske W; Fareed J
Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():41-7. PubMed ID: 15085465
[TBL] [Abstract][Full Text] [Related]
10. A supersulfated low-molecular-weight heparin (IK-SSH) increases plasma levels of free and total tissue factor pathway inhibitor after intravenous and subcutaneous administration in humans.
Kaiser B; Glusa E; Hoppensteadt DA; Breddin HK; Amiral J; Fareed J
Blood Coagul Fibrinolysis; 1998 Sep; 9(6):517-23. PubMed ID: 9819002
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of C-reactive protein on the release of tissue factor pathway inhibitor from human endothelial cells: reversal by low molecular weight heparin.
Mousa SA
Int Angiol; 2006 Mar; 25(1):10-3. PubMed ID: 16520718
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of unfractionated heparin, low molecular weight heparin and both combined for releasing total and free tissue factor pathway inhibitor.
Altman R; Scazziota A; Rouvier J
Haemostasis; 1998; 28(5):229-35. PubMed ID: 10420071
[TBL] [Abstract][Full Text] [Related]
13. Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis.
Hainer JW; Sherrard DJ; Swan SK; Barrett JS; Assaid CA; Fossler MJ; Cox DS; Williams RM; Pittenger AL; Stephenson CA; Hua TA
Am J Kidney Dis; 2002 Sep; 40(3):531-8. PubMed ID: 12200805
[TBL] [Abstract][Full Text] [Related]
14. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin.
Hoppensteadt DA; Walenga JM; Fasanella A; Jeske W; Fareed J
Thromb Res; 1995 Jan; 77(2):175-85. PubMed ID: 7740509
[TBL] [Abstract][Full Text] [Related]
15. Bemiparin and fluid flow modulate the expression, activity and release of tissue factor pathway inhibitor in human endothelial cells in vitro.
Westmuckett AD; Kakkar VV; Hamuro T; Lupu F; Lupu C
Thromb Haemost; 2001 Dec; 86(6):1547-54. PubMed ID: 11776326
[TBL] [Abstract][Full Text] [Related]
16. The effect of unfractionated vs. low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients.
Brown JR; Kuter DJ
Thromb Haemost; 2001 Jun; 85(6):979-85. PubMed ID: 11434705
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy.
Hansen JB; Sandset PM
Thromb Res; 1998 Aug; 91(4):177-81. PubMed ID: 9736420
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of the pharmacokinetic profiles of two LMWHs--bemiparin (3500 IU, anti-Xa) and tinzaparin (4500 IU, anti-Xa)--administered subcutaneously to healthy male volunteers.
Depasse F; González de Suso MJ; Lagoutte I; Fontcuberta J; Borrell M; Samama MM
Thromb Res; 2003 Jan; 109(2-3):109-17. PubMed ID: 12706639
[TBL] [Abstract][Full Text] [Related]
19. Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins? Biochemical considerations.
Ostergaard P; Nordfang O; Petersen LC; Valentin S; Kristensen H
Haemostasis; 1993 Mar; 23 Suppl 1():107-11. PubMed ID: 8388348
[TBL] [Abstract][Full Text] [Related]
20. Effect of intraperitoneal administration of low-molecular-weight heparin on plasma tissue factor pathway inhibitor levels in CAPD patients.
Demirkan F; Akarsu M; Sifil A; Tutucu KN
Nephron; 2002 May; 91(1):162-3. PubMed ID: 12021535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]